Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257264 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by BeiGene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 20
- Study locations
NCT06257264 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by BeiGene. The registered enrollment target is 258 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06257264, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC). The study will also identify a recommended dose for expansion (RDFE) for BG-68501 as monotherapy and in combination for subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion, including evaluation of food effect) and Part 2 (dose expansion).
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG BG-68501
- DRUG BGB-43395
Study Locations (20)
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Saint Vincents Hospital Sydney - Darlinghurst
- Nepean Hospital - Kingswood
- Genesiscare North Shore - St Leonards
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
California
- Hoag Memorial Presbyterian - Newport Beach
Florida
- Florida Cancer Specialists and Research Institute - Lake Mary
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Titan Health Partners Llc Dba Astera Cancer Care - East Brunswick
South Dakota
- Avera Cancer Institute - Sioux Falls
Texas
- Mary Crowley Cancer Research - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06257264
The ClinicalTrials.gov registry entry for NCT06257264 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT06257264 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New South Wales, Beijing Municipality, California.
Frequently Asked Questions
What is clinical trial NCT06257264 about?
NCT06257264 is a clinical study titled "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors". This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic ...
What is the current status of trial NCT06257264?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2024-03-11. Estimated completion is 2028-07.
What conditions does trial NCT06257264 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Advanced Solid Tumor, Endometrial Cancer.
What interventions are being tested in trial NCT06257264?
The interventions under investigation include: Fulvestrant (DRUG), BG-68501 (DRUG), BGB-43395 (DRUG).
Who is sponsoring clinical trial NCT06257264?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06257264 being conducted?
This trial has 20 study locations across California, Florida, Missouri, New Jersey, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.